How are you feeling today? Keep up to date on news and stories related to healthcare here!
Zoetis plans to immediately implement updated label based on U.S. post-approval experience with Librela Company remains confident in the safety and effectiveness of Librela and reaffirms its commitment to supporting veterinarians and pet owners in helping dogs with OA live with less
Now accepting applications for 2025 grants to accelerate innovation in tissue transplantation EDISON, N.J. — (BUSINESS WIRE) — MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, has awarded
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU to an earlier HR positive treatment setting and broadens the patient
Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up Late-breaking data presented in oral session at the 2025
PARSIPPANY, N.J. — (BUSINESS WIRE) — YARAL Pharma Inc. (YARAL Pharma), the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland, today announced that it will continue working with the Pharmacy Podcast Network (PPN), a
First approval in the U.S. for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy Second DXd antibody drug conjugate approved in U.S. based on Daiichi Sankyo’s DXd technology
OSAKA, Japan — (BUSINESS WIRE) — Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a $375 million project agreement through the Rapid
Components will be the first-in-human use of OSTAGUARD™ PRINCETON, N.J. — (BUSINESS WIRE) — Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, today announced the successful in-house production and commercial delivery
Dazed, the fastest growing cannabis brand on the East Coast and 5th LEGAL dispensary to open in NYC, is seeing their customers embrace the growing trend of California Sober. The increasingly popular lifestyle that allows for cannabis indulgences but opts out